PTCT:NGS-PTC Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 46.24

Change

0.00 (0.00)%

Market Cap

USD 0.40B

Volume

1.43M

Analyst Target

USD 60.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.00 (+2.01%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+13.28 (+1.89%)

USD 84.94B
ARGX argenx NV ADR

+4.50 (+0.72%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-3.18 (-1.30%)

USD 31.66B
BGNE BeiGene Ltd

+1.20 (+0.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+4.07 (+1.13%)

USD 16.18B
MRNA Moderna Inc

+0.20 (+0.51%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.33 (+1.32%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.80 (+4.48%)

USD 13.67B
INCY Incyte Corporation

+1.00 (+1.45%)

USD 13.52B

ETFs Containing PTCT

MSGR 6.14 % 0.00 %

N/A

N/A
IBRN iShares Trust - iShares N.. 6.05 % 0.00 %

+0.24 (+0%)

USD 3.86M
SBIO ALPS Medical Breakthrough.. 2.63 % 0.50 %

-0.01 (0%)

USD 0.11B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

-0.09 (0%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 67.78% 87% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.78% 87% B+ 90% A-
Trailing 12 Months  
Capital Gain 67.48% 86% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.48% 86% B+ 89% A-
Trailing 5 Years  
Capital Gain -7.02% 74% C 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.02% 74% C 41% F
Average Annual (5 Year Horizon)  
Capital Gain -4.16% 41% F 28% F
Dividend Return -4.16% 40% F 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.85% 77% C+ 52% F
Risk Adjusted Return -11.28% 36% F 28% F
Market Capitalization 0.40B 93% A 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1,743.27 0% 0%
Price / Cash Flow Ratio -23.68 92% 90%
Price/Free Cash Flow Ratio -10.22 91% 90%
Management Effectiveness  
Return on Equity -7,740.12% 0% 0%
Return on Invested Capital -35.51% 67% 28%
Return on Assets -5.15% 92% 41%
Debt to Equity Ratio -232.60% 93% 96%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector